Fingerprinting of the TLR4-induced acute inflammatory response

Experimental and Molecular Pathology

Volumn 93, Issue 3, 2012, Pages 319-323

  Bosmann, Markus ^a,b   Russkamp, Norman F ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Acute lung injury; Bead based assay; Endotoxemia; LPS; Shock

Indexed keywords

CXCL1 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CONTROLLED STUDY; ENDOTOXEMIA; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; MULTIPLEXING BEAD BASED ASSAY; NONHUMAN;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; ENDOTOXEMIA; ESCHERICHIA COLI; IMMUNOASSAY; INJECTIONS, INTRAPERITONEAL; INTUBATION, INTRATRACHEAL; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 84870664175     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.08.006     Document Type: Article

References (24)

1. Abraham E., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study group. JAMA: The Journal of the American Medical Association 1995, 273:934-941.
2. Abraham E., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 1998, 351:929-933.
3. Agbeko R.S., et al. Genetic polymorphisms in the endotoxin receptor may influence platelet count as part of the acute phase response in critically ill children. Intensive Care Medicine 2010, 36:1023-1032.
4. Beutler B., Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nature Reviews Immunology 2003, 3:169-176.
5. Bosmann M., et al. The outcome of polymicrobial sepsis is independent of T and B cells. Shock 2011, 36:396-401.
6. Bosmann M., et al. Anti-inflammatory effects of beta2 adrenergic receptor agonists in experimental acute lung injury. FASEB Journal 2012, 26:2137-2144.
7. Bosmann M., et al. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. Journal of Immunology (Baltimore, Md.: 1950) 2012, 188:5086-5093.
8. Chen L., et al. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. Journal of Immunology (Baltimore, Md.: 1950) 2006, 177:2373-2383.
9. Copeland S., et al. Acute inflammatory response to endotoxin in mice and humans. Clinical and Diagnostic Laboratory Immunology 2005, 12:60-67.
10. Fisher C.J., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. The New England journal of medicine 1996, 334:1697-1702.
11. Marsik C., et al. The toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms influence the late inflammatory response in human endotoxemia. Clinical Chemistry 2005, 51:2178-2180.
12. Matsuyama K. Eisai's Sepsis Drug Eritoran Fails to Save More Lives in Final-Stage Study 2011.
13. Michie H.R., et al. Detection of circulating tumor necrosis factor after endotoxin administration. The New England Journal of Medicine 1988, 318:1481-1486.
14. Pfeiffer R. Untersuchungen über das Choleragift. Medical Microbiology and Immunology 1892, 11:393-412.
15. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
16. Raetz C.R., Whitfield C. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 2002, 71:635-700.
17. Reid R.R., et al. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. Journal of Immunology (Baltimore, Md.: 1950) 1997, 159:970-975.
18. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Critical Care Medicine 2001, 29:S121-S125.
19. Sakula A. Robert Koch: the story of his discoveries in tuberculosis. Irish Journal of Medical Science 1985, 154:3-9.
20. Suffredini A.F., et al. The cardiovascular response of normal humans to the administration of endotoxin. The New England Journal of Medicine 1989, 321:280-287.
21. Sun Y., et al. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 2011, 117:6172-6183.
22. Tobias P.S., et al. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. The Journal of Experimental Medicine 1986, 164:777-793.
23. Wright S.D., et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
24. Yang I.V., et al. Novel regulators of the systemic response to lipopolysaccharide. American Journal of Respiratory Cell and Molecular Biology 2011, 45:393-402.